Profile data is unavailable for this security.
About the company
Vera Therapeutics, Inc. is a late-stage biotechnology company. The Company is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its product candidate, atacicept, is a self-administered fusion protein that blocks both a B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL) which stimulates B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. The Company is also engaged in developing MAU868, a monoclonal antibody designed to neutralize infection with BK Virus, a polyomavirus that can have devastating consequences in certain settings such as kidney transplants. The Company is conducting a randomized, double-blind, placebo-controlled Phase 3 clinical trial in IgAN, which it refers to as ORIGIN 3, and completing the open label extension of its Phase 2b clinical trial in IgAN, which it refers to as ORIGIN 2b.
- Revenue in USD (TTM)0.00
- Net income in USD-94.30m
- Incorporated2016
- Employees55.00
- LocationVera Therapeutics Inc8000 Marina Boulevard,, Suite 120BRISBANE 94005United StatesUSA
- Phone+1 (650) 770-0077
- Fax+1 (302) 655-5049
- Websitehttps://veratx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rocket Pharmaceuticals Inc | 0.00 | -249.31m | 1.90bn | 268.00 | -- | 4.30 | -- | -- | -2.87 | -2.87 | 0.00 | 4.87 | 0.00 | -- | -- | 0.00 | -49.16 | -35.26 | -52.49 | -37.49 | -- | -- | -- | -- | -- | -- | 0.0458 | -- | -- | -- | -10.70 | -- | 62.52 | -- |
| Catalyst Pharmaceuticals Inc | 411.35m | 65.12m | 1.96bn | 167.00 | 30.77 | 3.48 | 19.41 | 4.76 | 0.5384 | 0.5384 | 3.60 | 4.76 | 0.7806 | 3.60 | 8.76 | 2,463,156.00 | 12.36 | 25.42 | 14.19 | 29.81 | 86.74 | 85.63 | 15.83 | 30.87 | 4.83 | -- | 0.00 | 0.00 | 85.90 | 280.39 | -14.05 | -- | 20.21 | -- |
| Geron Corp | 520.00k | -201.40m | 1.99bn | 141.00 | -- | 5.70 | -- | 3,821.14 | -0.3464 | -0.3464 | 0.0009 | 0.5876 | 0.0012 | -- | 0.3225 | 3,687.94 | -44.41 | -51.32 | -54.44 | -64.90 | -- | -- | -38,729.81 | -19,949.13 | -- | -- | 0.1935 | -- | -60.23 | -25.97 | -29.76 | -- | 120.29 | -- |
| Beam Therapeutics Inc | 360.91m | -134.74m | 1.99bn | 436.00 | -- | 2.18 | -- | 5.52 | -1.74 | -1.74 | 4.54 | 11.10 | 0.2681 | -- | -- | 827,777.50 | -10.01 | -24.54 | -11.79 | -29.26 | -- | -- | -37.33 | -211.96 | -- | -- | 0.00 | -- | 520.01 | -- | 54.16 | -- | 20.78 | -- |
| Vera Therapeutics Inc | 0.00 | -94.30m | 2.03bn | 55.00 | -- | 5.72 | -- | -- | -2.04 | -2.04 | 0.00 | 6.49 | 0.00 | -- | -- | 0.00 | -29.99 | -- | -31.92 | -- | -- | -- | -- | -- | -- | -- | 0.124 | -- | -- | -- | -7.79 | -- | -- | -- |
| Amphastar Pharmaceuticals Inc | 676.21m | 154.69m | 2.05bn | 1.76k | 14.47 | 3.05 | 10.21 | 3.04 | 2.90 | 2.90 | 12.70 | 13.77 | 0.576 | 2.79 | 5.66 | 383,991.50 | 13.33 | 9.42 | 15.75 | 11.56 | 54.73 | 47.83 | 23.14 | 15.23 | 1.72 | 8.48 | 0.4692 | 0.00 | 29.14 | 16.94 | 50.51 | -- | -4.00 | -- |
| Kymera Therapeutics Inc | 79.41m | -154.59m | 2.06bn | 186.00 | -- | 2.89 | -- | 25.91 | -2.50 | -2.50 | 1.29 | 11.59 | 0.1072 | -- | 29.69 | 424,668.40 | -20.86 | -23.03 | -22.67 | -27.64 | -- | -- | -194.67 | -207.82 | -- | -- | 0.0032 | -- | 67.84 | -- | 5.07 | -- | 91.01 | -- |
| Amneal Pharmaceuticals Inc | 2.50bn | -168.69m | 2.10bn | 7.70k | -- | -- | 19.68 | 0.8399 | -0.5642 | -0.5642 | 11.52 | -0.2065 | 0.7046 | 2.94 | 4.11 | 324,059.50 | -3.40 | -4.80 | -4.27 | -5.93 | 35.28 | 34.76 | -4.82 | -9.00 | 0.97 | 1.27 | 1.01 | -- | 8.20 | 7.56 | 35.38 | -- | -6.55 | -- |
| Myriad Genetics, Inc. | 774.20m | -234.60m | 2.11bn | 2.70k | -- | 2.78 | -- | 2.73 | -2.82 | -2.82 | 9.11 | 8.40 | 0.6792 | 10.41 | 6.53 | 286,740.80 | -20.58 | -- | -23.57 | -- | 68.79 | -- | -30.30 | -- | 1.82 | -225.20 | 0.0485 | -- | 11.03 | -- | -135.09 | -- | -- | -- |
| Recursion Pharmaceuticals Inc | 46.24m | -354.11m | 2.14bn | 500.00 | -- | 5.32 | -- | 46.21 | -1.62 | -1.62 | 0.2112 | 1.69 | 0.078 | -- | 19.86 | 92,470.00 | -59.76 | -- | -69.49 | -- | 10.66 | -- | -765.90 | -- | -- | -- | 0.0028 | -- | 11.88 | -- | -36.99 | -- | -- | -- |
| CG Oncology Inc | 539.00k | -72.33m | 2.16bn | 61.00 | -- | 3.80 | -- | 4,009.54 | -1.13 | -1.13 | 0.0084 | 8.54 | -- | -- | -- | 8,836.07 | -- | -- | -- | -- | -- | -- | -10,551.39 | -- | -- | -- | 0.00 | -- | 6.81 | -- | -54.83 | -- | -- | -- |
| Novavax Inc | 996.61m | -398.71m | 2.18bn | 1.54k | -- | -- | -- | 2.19 | -3.18 | -3.18 | 8.46 | -6.18 | 0.6882 | 14.75 | 14.85 | 645,890.50 | -27.53 | -46.06 | -460.95 | -269.57 | 63.04 | -- | -40.01 | -75.94 | 0.8843 | -27.04 | -- | -- | -50.36 | 95.68 | 17.16 | -- | 108.28 | -- |
| Intellia Therapeutics Inc | 52.60m | -485.50m | 2.19bn | 526.00 | -- | 2.11 | -- | 41.67 | -5.37 | -5.37 | 0.5827 | 10.76 | 0.0393 | -- | 2.55 | 100,007.60 | -36.27 | -31.34 | -39.21 | -34.53 | -- | -- | -922.94 | -654.71 | -- | -- | 0.00 | -- | -30.40 | 3.57 | -1.48 | -- | 17.08 | -- |
| Agios Pharmaceuticals Inc | 29.40m | -352.62m | 2.20bn | 383.00 | -- | 2.96 | -- | 74.94 | -6.31 | -6.31 | 0.5257 | 13.11 | 0.0294 | 0.1715 | 11.24 | 76,770.23 | -35.24 | -29.54 | -37.04 | -31.88 | 89.95 | -- | -1,199.26 | -3,826.10 | 12.39 | -- | 0.00 | -- | 88.36 | -22.25 | -51.89 | -- | -32.23 | -- |
| ADMA Biologics Inc | 283.18m | -3.64m | 2.20bn | 624.00 | -- | 14.34 | 462.27 | 7.78 | -0.0204 | -0.0204 | 1.23 | 0.6632 | 0.8188 | 0.9923 | 7.44 | 453,808.40 | -1.05 | -24.80 | -1.21 | -28.00 | 40.13 | 17.40 | -1.29 | -51.31 | 1.86 | 2.19 | 0.4598 | -- | 67.59 | 72.34 | 57.15 | -- | 18.91 | -- |
Data as of May 28 2024. Currency figures normalised to Vera Therapeutics Inc's reporting currency: US Dollar USD
47.61%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Avoro Capital Advisor LLCas of 31 Mar 2024 | 5.27m | 9.59% |
| Commodore Capital LPas of 31 Mar 2024 | 3.17m | 5.76% |
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 3.12m | 5.69% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 2.99m | 5.45% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 2.35m | 4.28% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 2.33m | 4.24% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 2.07m | 3.76% |
| Eversept Partners LPas of 31 Mar 2024 | 1.82m | 3.32% |
| Kynam Capital Management LPas of 31 Mar 2024 | 1.53m | 2.78% |
| Morgan Stanley & Co. LLCas of 31 Mar 2024 | 1.51m | 2.74% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
